From Diagnosis to Recovery: Everything You Need to Know About Non-Small Cell Lung Cancer (NSCLC)

Non-Small Cell Lung Cancer (NSCLC) belong to a group of lung cancers that originates in the lung tissues but are different from the faster-growing & more serious type known as Small Cell Lung Cancer (SCLC). NSCLC is the most common type of lung cancer that contribute to approximately 80-85% of cases globally.

In this cancer abnormal cells in the lungs multiply uncontrollably, leading to a tumor that can affect surrounding tissues or spread (metastasize) to other parts of the body. Due to the slower growth rate (as compared to small-cell lung cancer), symptoms can appear later, resulting in late diagnosis. Because of how common it is and the wide range of treatment options available today, including surgery, radiation, chemotherapy, targeted treatments, and immunotherapy, NSCLC is an important area of lung cancer clinical trials and research.

NSCLC vs. Small Cell Lung Cancer (SCLC): Key Differences  

Causes and Risk Factors of NSCLC  

There are many factors that can increase the risk of NSCLC. Some of the major ones:
Smoking: This is the most dangerous factor. Many NSCLCs have a major connection with present or previous cigarette smoking.
Secondhand Smoke: Exposure to tobacco smoke via others can highly raise the chance of developing lung cancer.
Environmental exposures: Environmental exposures such as radon gas, asbestos, metal or mineral dust, and air pollution.
Previous radiation therapy: Previous radiation therapy, like radiation treatments to the chest, may increase the chance of getting lung cancer.
Genetic factors & mutations: While most NSCLC is not inherited, certain gene mutations like like EGFR, ALK, KRAS, etc. Impact to the cancer's development and might impact risk or therapy.
Lung disease history: Conditions such as COPD or fibrosis may raise risk.
Understanding this can be useful for both prevention and changing screening or early detection techniques.

Common Symptoms of NSCLC  

NSCLC can develop slowly and without symptoms initially, which makes it difficult to diagnose until the cancer has advanced.

Common symptoms include:

• An ongoing or worsening cough.

• Coughing up blood or brightly colored sputum.

• Chest discomfort, particularly after hard breathing, coughing, or laughing.

• Shortness of breath & wheezing.

• Hoarseness or vocal alterations.

• Loss of appetite or unintentional weight loss.

• Fatigue & muscular weakness.

• Chronic respiratory infections (bronchitis, pneumonia) that do not resolve.

If the cancer has spread (metastasized), symptoms may include:

• Bone pain

• Headaches

• Swelling of the face or neck (in superior vena cava syndrome)

• Neurological problems.

How NSCLC is Diagnosed 

The diagnosis of NSCLC consist multiple steps:

• Medical history and physical examination:It includes evaluating symptoms, smoking history, exposure history, & physical indications.  

• Imaging tests:

• A chest X-ray or a low-dose CT scan must be performed to detect any abnormalities.

• CT scan of the chest, which sometimes may involve the abdomen and pelvis.  

• PET scan for identifying metabolic activity & spread.

• An MRI may be performed (especially when tumors in the brain are suspected).

• Biopsy:It is the process of obtaining tissue samples via bronchoscopy, a CT-guided needle, or surgical biopsy. It helps to detect the type of cancer.

• Molecular/Genetic testing: For certain gene mutations (EGFR, ALK, ROS1 etc) which guide targeted therapy decisions.

• Staging tests:In order to determine exactly how far the cancer has spread, examine lymph nodes along with additional organs (bone scan, brain imaging, etc.).
  Accurate diagnosis along with staging play an essential role for selecting a suitable therapy plan.

Stages of Non-Small Cell Lung Cancer  

Staging shows the level to which the cancer has spread and tumor necrosis method is commonly used for it. NSCLC can be divided into the following major stages:
Carcinoma in situ seems a very early stage of cancer which impacts only one location.
Stage I: A localized tumor in the lung with no spreading to lymph nodes.
Stage II: The cancer may be more extensive or impact lymph nodes on the same side of the chest.
Stage III: more severe stage that involve lymph nodes and possibly chest tissues are also involved, but no distant metastases has occurred.
Stage IV: Cancer has spread to other organs (brain, bone, liver, etc.).
Treatment and prognosis vary widely depending on stage. Early stages are more likely to be treated successfully, whereas later stages focus on control the infection and improving quality of life.

 Treatment Options for NSCLC 

Treatment options depends on the stage of cancer, tumour’s genetic profile, patient’s overall health, and other factors. Main modalities:

Surgery  

For early-stage NSCLC (I or some II) where the tumor can be removed, surgery to remove part or total lung lobe (lobectomy, pneumonectomy) may be recommended. This aims to cure whenever possible.

Radiation Therapy  

High-energy X-rays (or other particles) are used to kill cancer cells. Radiation may be used:

• As the main treatment when surgery isn’t possible

• After surgery (adjuvant) to kill residual disease

• For palliative purposes to relieve symptoms (pain, airway obstruction)

Chemotherapy  

Standard systemic drug treatment that attacks rapidly dividing cells (including cancer). May be used:

• Before surgery (neoadjuvant) to shrink tumor

• After surgery (adjuvant) to reduce recurrence

• In advanced disease to slow progression and relieve symptoms

Targeted Therapy (Iressa, Erlonat)  

Targeted therapies act on specific molecular features of the cancer cells. Examples:

• Iressa (gefitinib) is an EGFR tyrosine-kinase inhibitor used in NSCLC with specific EGFR mutations (exon 19 deletions or exon 21 L858R substitutions) and metastatic disease.

• Erlonat (erlotinib) also targets EGFR mutated tumours.
  Targeted therapy often has fewer side effects than standard chemo and can yield good outcomes in selected patients.

Immunotherapy  

These treatments boost the body’s immune system to recognise and destroy cancer cells. Examples include immune-checkpoint inhibitors. Recent trials show adding immunotherapy before surgery improves long-term survival.

In many cases, a combination of treatments is used (e.g., surgery + chemo + targeted therapy). Recent research is bringing newer therapies and precision medicine into NSCLC care.

Living with NSCLC: Lifestyle and Support  

Living with NSCLC doesn’t mean giving up on life.
Here are the following ways to support life quality and wellness during this journey:

• Quit smoking (if you smoke) & also avoid second-hand smoke.

• Healthy eating: Taking proper balanced diet rich in fruits, vegetables, lean protein is essential.

• Regular exercise as permitted by your doctor to help mobility, energy, lung function.

• Manage side-effects of treatments (nausea, fatigue, breathlessness) with your medical team.

• Emotional support: a cancer diagnosis can be traumatic; support groups, counseling, family-involvement help.

• Palliative care early: even when the goal isn’t cure, palliative care can improve quality of life and reduce symptoms.

• Stay informed and involved: ask about molecular testing, clinical trials, new therapy options.

Prevention and Early Detection 

Although not all NSCLCs are preventable but many risk factors can be improved.
Here are some prevention and early detection strategies:

• Stop smoking, and avoid exposure to tobacco smoke.

• Avoid known carcinogens such as asbestos, radon, certain chemicals, etc.

• Maintain a healthy lifestyle to reduce risk. Regular exercise can also help.

• Screening in high-risk individuals, for example people aged under 50-80 with heavy smoking history may be given annual low-dose CT scans.

• Awareness of symptoms like early cough, hoarseness, etc. should require evaluation and early diagnosis improves outcomes.

  
  

Iressa 250 mg Tablet Uses in NSCLC Treatment

​

Iressa (gefitinib) 250 mg is an oral targeted medication used in the treatment of NSCLC under the following conditions:

• It is suggested as the first-line therapy of adult patients with metastatic NSCLC whose tumors contain EGFR exon 19 deletions or exon 21 (L858R) substitution mutations as determined by an FDA-approved test.

• It works by blocking the EGFR tyrosine kinase enzyme. That results in inhibiting signals that promote cancer cell growth & survival.

• Rash, diarrhea, and liver problems are possible side effects. For the best possible results, individuals with EGFR mutations must be carefully selected.

• It cannot be used for all NSCLC patients, but only those whose tumors test positive for specific EGFR mutations.

Thus, for patients with NSCLC with an EGFR-positive mutation, Iressa offers a precision medicine alternative with potentially better results and fewer side effects than conventional chemotherapy.

Conclusion

Non-Small Cell Lung Cancer (NSCLC) is one of the most common and life threatening lung cancer. Although modern advancements in diagnosis, targeted therapy, & immunotherapy make treatment considerably more effective than previous ones. Early detection with regular examinations may increase survival rates. Iressa 250 mg (gefitinib) is a medication that has improved focused treatment for patients with certain EGFR mutations and help to prevent disease progression.

You can avail this medicine from Magicine Pharma as we supports both patients and caregivers all along their treatment journey with affordable and trustworthy treatment options for cancer.  By increasing awareness, promoting early diagnosis, and providing trustworthy medicines, we can make NSCLC more manageable while enhancing the quality of life.

FAQs

Can non small cell lung cancer be cured?
A-Yes it can be cured only of detected in early (Stage I or II) and treated with appropriate surgery and adjuvant therapy. Later stages are more difficult to cure but can be managed.

How fast does NSCLC spread and grow?
A-Growth rate varies widely like some tumours grow slowly and others more quickly. It depends on sub-type, mutation status, and patient health factors.

Does everyone with NSCLC require genetic testing?
A-Yes according to modern practice because targeted therapies depend on identifying whether the tumor has specific mutations (EGFR, ALK, ROS1, etc).

What is the difference between targeted therapy and chemotherapy?
A-Chemotherapy works on rapidly dividing cells and general targeted therapy attacks specific molecular mutations in the cancer cells. Targeted therapy offers fewer side-effects and better response in the right patient.

If  I’ve quit smoking many years ago, am I still at risk?
A-Yes, quitting smoking reduces but does not eliminate risk. Other exposures like environmental  & genetic may still contribute. Thus, symptom awareness & screening are important.

References:

1. National Cancer Institute – Advances in Lung Cancer Research for NSCLC. (Cancer.gov)

2. GoodRx – Gefitinib (Iressa) uses and details for NSCLC. (GoodRx)

3. Mayo Clinic – Gefitinib description. (Mayo Clinic)

4. Su PL et al., “Recent advances in therapeutic strategies for non-small cell lung cancer”, JHOonline (2025). (BioMed Central)

5. Cleveland Clinic – NSCLC overview and symptoms. (Cleveland Clinic)